Skip to search formSkip to main contentSkip to account menu

SKI-606

Known as: SKI 606, SKI606 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

bosutinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
Cortes JE, Kantarjian HM, Brümmendorf TH, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or…
On pages 4568, 4572, 4574, and 4576 of the 27 October 2011 issue, there are errors in the text. On page 4568 in the “Study design… 
Highly Cited
2011
Highly Cited
2011
Identification of a Src Tyrosine Kinase/SIAH2 E3 Ubiquitin Ligase Pathway That Regulates C/EBPδ Expression and Contributes to Transformation of Breast Tumor Cells
ABSTRACT The transcription factor CCAAT/enhancer-binding protein delta (C/EBPδ, CEBPD) is a tumor suppressor that is… 
2011
2011
Conventional risk factors among newly diagnosed coronary heart disease patients in Delhi.
AIM To analyze the conventional risk factors among newly diagnosed cases of coronary heart disease (CHD) admitted to a hospital… 
2011
2011
Disruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo.
Ras/MEK/ERK pathway activation represents an important compensatory response of human multiple myeloma (MM) cells to checkpoint… 
2010
2010
An Ongoing Phase 3 Study of Bosutinib (SKI-606) Versus Imatinib In Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Abstract 208 Bosutinib is an orally bioavailable dual Src/Abl tyrosine kinase inhibitor (TKI), with minimal inhibitory activity… 
2010
2010
Safety and efficacy of bosutinib (SKI-606) in patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML) following resistance or intolerance to imatinib (IM).
6502 Background: Bosutinib is an orally bioavailable dual Src/Abl tyrosine kinase inhibitor, with minimal inhibitory activity… 
2009
2009
Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts
Recently, Src tyrosine kinase has emerged as an attractive target for anticancer therapy, and Src is overexpressed in pancreatic… 
2009
2009
SKI-606 and beyond
4-Phenylamino-3-quinolinecarbonitriles have been extensively studied by Wyeth as inhibitors of diverse kinases including EGFR… 
Review
2006
Review
2006
New tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.
Imatinib mesylate, Abl tyrosine kinase inhibitor, has improved the treatment of Bcr-Abl-positive leukemia such as chronic myeloid… 
Highly Cited
2005
Highly Cited
2005
3D-QSAR studies on c-Src kinase inhibitors and docking analyses of a potent dual kinase inhibitor of c-Src and c-Abl kinases.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)